{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:25:07Z","timestamp":1787739907048,"version":"build-2784847793"},"reference-count":43,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Patients with amiodarone-induced thyrotoxicosis (AIT) often receive initial therapy for thyrotoxicosis in several different medical settings before admission to a referral center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This work aimed to determine whether first-line medical therapy (ie, therapies for thyrotoxicosis at first diagnosis of AIT) affects the outcome of AIT patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single-center historical-prospective cohort study was conducted on 313 AIT patients. Clinical and biochemical data were collected at first diagnosis, at a referral center, and during the course of AIT. Primary outcomes were cardiovascular (CV) events and hospitalizations. First-line therapies were considered appropriate when they included glucocorticoids for type 2 AIT and methimazole for type 1 AIT at the approved dose, either alone (optimal medical therapy, OMT) or in combination (right-dose combination therapy, RCT). Other therapies were considered not appropriate, including no therapy. Duration of exposure to thyrotoxicosis was the time from first diagnosis of AIT to its remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 34.5% patients received appropriate therapies (28.1% OMT, 6.4% RCT), whereas the remaining (65.5%) received inappropriate therapies. CV events and hospitalizations were more frequent in patients who received inappropriate therapies (33.2% vs 4.5%, and 24.9% vs 6.5%, respectively; P &amp;lt; .0001 for both). Appropriate therapies reduced serum thyroid hormone concentrations (P = .018) from first diagnosis to referral, unlike the inappropriate therapies. The duration of exposure to thyrotoxicosis was longer in patients receiving inappropriate therapies and was a risk factor for arrhythmias (hazard ratio [HR] 1.004; P = .0008), major acute CV events (HR 1.004; P = .020), and hospitalizations (HR 1.006; P &amp;lt; .0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The first medical therapy of AIT influences the exposure time to thyrotoxicosis and the occurrence of CV events and hospitalizations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac756","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T11:51:41Z","timestamp":1672487501000},"page":"1298-1307","source":"Crossref","is-referenced-by-count":15,"title":["Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-3561","authenticated-orcid":false,"given":"Daniele","family":"Cappellani","sequence":"first","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marconcini","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Manetti","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8447-5449","authenticated-orcid":false,"given":"Luigi","family":"Bartalena","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria , 21100 Varese , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-4411","authenticated-orcid":false,"given":"Fausto","family":"Bogazzi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa , 56124 Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"issue":"2","key":"2023051701085684500_dgac756-B1","first-page":"240","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocr Rev"},{"issue":"6","key":"2023051701085684500_dgac756-B2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.beem.2009.07.001","article-title":"Amiodarone and thyroid","volume":"23","author":"Eskes","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023051701085684500_dgac756-B3","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211001165","article-title":"Amiodarone-induced thyroid dysfunction in children: insights from the THYRAMIO study","volume":"12","author":"Montenez","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"24","key":"2023051701085684500_dgac756-B4","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2007.02.054","article-title":"Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome","volume":"49","author":"Conen","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2023051701085684500_dgac756-B5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1210\/clinem\/dgz041","article-title":"Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxicosis","volume":"105","author":"Cappellani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023051701085684500_dgac756-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/jc.2008-1907","article-title":"Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome","volume":"94","author":"Yiu","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023051701085684500_dgac756-B7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"10","key":"2023051701085684500_dgac756-B8","first-page":"1463","article-title":"Identification of two different phenotypes of patients with amiodarone-induced thyrotoxicosis and positive thyrotropin receptor antibody tests","volume":"31","author":"Cappellani","year":"2021","journal-title":"Thyroid"},{"key":"2023051701085684500_dgac756-B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-030-36871-5_23","volume-title":"Thyroid and Heart: A Comprehensive Translational Essay","author":"Bogazzi","year":"2020"},{"issue":"1","key":"2023051701085684500_dgac756-B10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1210\/clinem\/dgaa686","article-title":"Evaluation and treatment of amiodarone-induced thyroid disorders","volume":"106","author":"Ylli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023051701085684500_dgac756-B11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023051701085684500_dgac756-B12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/thy.2018.0320","article-title":"Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk","volume":"29","author":"Lillevang-Johansen","year":"2019","journal-title":"Thyroid"},{"issue":"7","key":"2023051701085684500_dgac756-B13","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1210\/jc.2017-00166","article-title":"Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low Serum TSH","volume":"102","author":"Lillevang-Johansen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023051701085684500_dgac756-B14","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1210\/clinem\/dgaa464","article-title":"Duration of exposure to thyrotoxicosis increases mortality of compromised AIT patients: the role of early thyroidectomy","volume":"105","author":"Cappellani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023051701085684500_dgac756-B15","article-title":"Supplementary data for \u201cReal-life data on the impact of first-line medical therapy for amiodarone-induced thyrotoxicosis on cardiovascular events and hospitalizations.\u201d","author":"Cappellani","journal-title":"Mendeley Data"},{"issue":"3","key":"2023051701085684500_dgac756-B16","first-page":"340","article-title":"Amiodarone and the thyroid: a 2012 update","volume":"35","author":"Bogazzi","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2023051701085684500_dgac756-B17","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2012-1797","article-title":"Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction","volume":"97","author":"Tomisti","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023051701085684500_dgac756-B18","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1210\/jc.2010-0180","article-title":"Approach to the patient with amiodarone-induced thyrotoxicosis","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023051701085684500_dgac756-B19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"2023051701085684500_dgac756-B20","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-030185","article-title":"Antithyroid drugs in the management of patients with Graves\u2019 disease: an evidence-based approach to therapeutic controversies","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023051701085684500_dgac756-B21","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1210\/jc.2011-1678","article-title":"Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study","volume":"96","author":"Bogazzi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023051701085684500_dgac756-B22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/EJE-16-0562","article-title":"Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly","volume":"175","author":"Sardella","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023051701085684500_dgac756-B23","doi-asserted-by":"crossref","first-page":"e030017","DOI":"10.1136\/bmjopen-2019-030017","article-title":"Associations between community well-being and hospitalisation rates: results from a cross-sectional study within six US states","volume":"9","author":"Roy","year":"2019","journal-title":"BMJ Open"},{"issue":"7","key":"2023051701085684500_dgac756-B24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjcard.2009.11.035","article-title":"Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating to New Targets [TNT] trial)","volume":"105","author":"Ho","year":"2010","journal-title":"Am J Cardiol"},{"issue":"2","key":"2023051701085684500_dgac756-B25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12020-022-03028-5","article-title":"Salvage total thyroidectomy for amiodarone-induced thyrotoxicosis in a SARS-CoV-2 positive patient: results of the viral genome research on the pathology sample of this destructive thyroiditis","volume":"76","author":"Cappellani","year":"2022","journal-title":"Endocrine"},{"issue":"5","key":"2023051701085684500_dgac756-B26","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"Anniversary review: antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023051701085684500_dgac756-B27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"2023051701085684500_dgac756-B28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF03349025","article-title":"Color flow Doppler sonography in thyrotoxicosis factitia","volume":"19","author":"Bogazzi","year":"1996","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2023051701085684500_dgac756-B29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/thy.1997.7.541","article-title":"Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis","volume":"7","author":"Bogazzi","year":"1997","journal-title":"Thyroid"},{"issue":"7","key":"2023051701085684500_dgac756-B30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF03347021","article-title":"Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis","volume":"26","author":"Bogazzi","year":"2003","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2023051701085684500_dgac756-B31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jacc.2006.08.042","article-title":"Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study","volume":"49","author":"Osman","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2023051701085684500_dgac756-B32","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1210\/jc.2013-4184","article-title":"Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study","volume":"99","author":"Selmer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023051701085684500_dgac756-B33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/eje.1.02122","article-title":"Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality","volume":"154","author":"O'Sullivan","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2023051701085684500_dgac756-B34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/01.CIR.0000085166.44904.79","article-title":"Natural history of asymptomatic left ventricular systolic dysfunction in the community","volume":"108","author":"Wang","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"2023051701085684500_dgac756-B35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.290.8.1049","article-title":"A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study","volume":"290","author":"Wang","year":"2003","journal-title":"JAMA"},{"issue":"11","key":"2023051701085684500_dgac756-B36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40618-020-01252-2","article-title":"Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study","volume":"43","author":"Cappellani","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2023051701085684500_dgac756-B37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1210\/jc.2006-2059","article-title":"Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023051701085684500_dgac756-B38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2265.2004.02119.x","article-title":"Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association","volume":"61","author":"Bartalena","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2023051701085684500_dgac756-B39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1365-2265.2008.03268.x","article-title":"Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists","volume":"69","author":"Tanda","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023051701085684500_dgac756-B40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2265.2006.02590.x","article-title":"Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey","volume":"65","author":"Diehl","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023051701085684500_dgac756-B41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2265.2008.03350.x","article-title":"Benzofuran derivatives and the thyroid","volume":"70","author":"Han","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2023051701085684500_dgac756-B42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrendo.2009.218","article-title":"Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis","volume":"5","author":"Vanderpump","year":"2009","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2023051701085684500_dgac756-B43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/thy.2018.0274","article-title":"Increased risk of antithyroid drug agranulocytosis associated with amiodarone-induced thyrotoxicosis: a population-based cohort study","volume":"29","author":"Gershinsky","year":"2019","journal-title":"Thyroid"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac756\/48831713\/dgac756.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/6\/1298\/50355127\/dgac756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/6\/1298\/50355127\/dgac756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:11:18Z","timestamp":1684285878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/6\/1298\/6966147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,31]]},"published-print":{"date-parts":[[2023,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac756","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2022,12,31]]}}}